Skip to main content

Table 2 Geometric mean and 95% confidence interval for sex hormone concentrations, separately for placebo and active randomization groups for breast cancer cases and controls from the Women’s Health Initiative CEE + MPA trial

From: Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects

  CEE + MPA trial
  Placebo Active treatment
  Cases Controls P-value* Cases Controls P-value*
Estradiol (pg/ml)       
Baseline 11.97 (4.96, 28.84) 10.05 (4.36, 23.17) 0.001 10.90 (4.83, 24.59) 10.89 (4.19, 28.34) 0.99
Year 1 10.12 (3.56, 28.71) 8.46 (2.86, 25.02) 0.008 22.30 (7.88, 63.06) 20.78 (6.02, 71.72) 0.28
Bioavailable estradiol (pg/ml)       
Baseline 8.02 (2.89, 22.25) 6.47 (2.49, 16.85) 0.001 7.10 (2.71, 18.60) 7.00 (2.31, 21.16) 0.82
Year 1 6.75 (2.16, 21.06) 5.35 (1.52, 18.76) 0.002 9.95 (3.75, 26.38) 9.98 (3.14, 31.71) 0.96
Estrone (pg/ml)       
Baseline 41.81 (17.36, 95.94) 35.20 (14.99, 82.68) 0.007 36.95 (16.06, 85.03) 36.37 (15.79, 83.74) 0.74
Year 1 37.68 (13.99, 101.49) 34.39 (13.78, 85.81) 0.14 117.48 (30.97, 445.66) 103.96 (23.00, 469.86) 0.14
Estrone sulfate (ng/ml) baseline 0.84 0.79 0.26 0.82 0.80 0.65
  (0.37, 1.91) (0.33, 1.88)   (0.33, 2.08) (0.29, 2.18)  
Year 1 0.75 (0.34, 1.67) 0.69 (0.30, 1.59) 0.17 1.88 (0.61, 5.81) 1.77 (0.51, 6.14) 0.37
SHBG (Nmol/L)       
Baseline 36.93 (15.05, 90.63) 41.94 (17.28, 101.80) 0.02 40.49 (14.99, 109.42) 39.81 (14.63, 108.31) 0.76
Year 1 37.37 (14.22, 98.23) 41.86 (16.51, 106.11) 0.06 95.46 (31.96, 285.11) 90.07 (30.96, 262.06) 0.35
  1. Samples are excluded if changes from baseline to year 1 log-transformed concentrations are outside the interquartile range by twice its width.
  2. *P-value from Student’s t-test comparison of case versus control values. CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate; SHBG, sex hormone binding globulin.